Eisai Submits Marketing Authorization Application for Lecanemab to UK MHRA

Eisai China Official WeChat Announcement: On May 22, Eisai submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lecanemab. Lecanemab is an investigational anti-amyloid-beta (Aβ) protofibril antibody for the treatment of early Alzheimer's disease (AD) confirmed to have amyloid pathology in the brain and mild AD-induced cognitive impairment.